Showing papers by "Jens Allmer published in 2021"

Novel perspectives for SARS-CoV-2 genome browsing.

Abstract: SARS-CoV-2 has spread worldwide and caused social, economic, and health turmoil. The first genome assembly of SARS-CoV-2 was produced in Wuhan, and it is widely used as a reference. Subsequently, more than a hundred additional SARS-CoV-2 genomes have been sequenced. While the genomes appear to be mostly identical, there are variations. Therefore, an alignment of all available genomes and the derived consensus sequence could be used as a reference, better serving the science community. Variations are significant, but representing them in a genome browser can become, especially if their sequences are largely identical. Here we summarize the variation in one track. Other information not currently found in genome browsers for SARS-CoV-2, such as predicted miRNAs and predicted TRS as well as secondary structure information, were also added as tracks to the consensus genome. We believe that a genome browser based on the consensus sequence is better suited when considering worldwide effects and can become a valuable resource in the combating of COVID-19. The genome browser is available at http://cov.iaba.online.

Classification of Precursor MicroRNAs from Different Species Based on K-mer Distance Features

Abstract: MicroRNAs (miRNAs) are short RNA sequences that are actively involved in gene regulation. These regulators on the post-transcriptional level have been discovered in virtually all eukaryotic organisms. Additionally, miRNAs seem to exist in viruses and might also be produced in microbial pathogens. Initially, transcribed RNA is cleaved by Drosha, producing precursor miRNAs. We have previously shown that it is possible to distinguish between microRNA precursors of different clades by representing the sequences in a k-mer feature space. The k-mer representation considers the frequency of a k-mer in the given sequence. We further hypothesized that the relationship between k-mers (e.g., distance between k-mers) could be useful for classification. Three different distance-based features were created, tested, and compared. The three feature sets were entitled inter k-mer distance, k-mer location distance, and k-mer first–last distance. Here, we show that classification performance above 80% (depending on the evolutionary distance) is possible with a combination of distance-based and regular k-mer features. With these novel features, classification at closer evolutionary distances is better than using k-mers alone. Combining the features leads to accurate classification for larger evolutionary distances. For example, categorizing Homo sapiens versus Brassicaceae leads to an accuracy of 93%. When considering average accuracy, the novel distance-based features lead to an overall increase in effectiveness. On the contrary, secondary-structure-based features did not lead to any effective separation among clades in this study. With this line of research, we support the differentiation between true and false miRNAs detected from next-generation sequencing data, provide an additional viewpoint for confirming miRNAs when the species of origin is known, and open up a new strategy for analyzing miRNA evolution.

Systems analysis of miRNA biomarkers to inform drug safety

Abstract: microRNAs (miRNAs or miRs) are short non-coding RNA molecules which have been shown to be dysregulated and released into the extracellular milieu as a result of many drug and non-drug-induced pathologies in different organ systems. Consequently, circulating miRs have been proposed as useful biomarkers of many disease states, including drug-induced tissue injury. miRs have shown potential to support or even replace the existing traditional biomarkers of drug-induced toxicity in terms of sensitivity and specificity, and there is some evidence for their improved diagnostic and prognostic value. However, several pre-analytical and analytical challenges, mainly associated with assay standardization, require solutions before circulating miRs can be successfully translated into the clinic. This review will consider the value and potential for the use of circulating miRs in drug-safety assessment and describe a systems approach to the analysis of the miRNAome in the discovery setting, as well as highlighting standardization issues that at this stage prevent their clinical use as biomarkers. Highlighting these challenges will hopefully drive future research into finding appropriate solutions, and eventually circulating miRs may be translated to the clinic where their undoubted biomarker potential can be used to benefit patients in rapid, easy to use, point-of-care test systems.